|Bid||9.50 x 800|
|Ask||9.99 x 800|
|Day's range||9.52 - 9.84|
|52-week range||7.48 - 14.14|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Puma Biotechnology reports inducement awards granted in May 2021 as required under Nasdaq Listing Rule 5635(c)(4) .
Puma Biotechnology presented data from the EGFR Exon 18-mutant NSCLC cohort of the Phase II SUMMIT Trial on June 4 at the 2021 ASCO Annual Meeting.
Puma Biotechnology presented data from the Phase II CONTROL Trial regarding neratinib dose escalation at the ASCO 2021 Annual Meeting.